|
In March 2026, the Center for Drug Evaluation and Research (CDER), US FDA issued a draft guidance for industry titled “New Clinical Investigation Exclusivity (3 years exclusivity) for drug products: Questions and answers.” The publication of this guidance has once again brought the need for clarity on this important regulatory provision into discussion. Exclusivity provisions play a critical role in the pharmaceutical regulatory framework because they serve as incentives for innovation. The new draft guidance seeks to provide additional clarification regarding the statutory and regulatory criteria for eligibility for 3-year exclusivity, also known as New Clinical Investigation Exclusivity, and outlines recommendations on the content and format of requests submitted by applicants seeking this protection.
The US FDA recognizes several types of exclusivities that provide different durations of market protection depending on the nature of the innovation and the statutory provisions involved. These include:
• Orphan Drug Exclusivity (ODE) - 7 years.
• New Chemical Entity Exclusivity (NCE) - 5 years.
• Generating Antibiotic Incentives Now (GAIN) Exclusivity - 5 years added to certain exclusivities.
• Pediatric Exclusivity (PED) - 6 months added to existing patents or regulatory exclusivities.
• Patent Challenge Exclusivity (PC) - 180 days (applicable only to Abbreviated New Drug Applications or ANDAs).
• Competitive Generic Therapy (CGT) Exclusivity - 180 days (also applicable only to ANDAs).
Each of these exclusivities serves a different policy objective. For example, orphan drug exclusivity is intended to promote the development of medicines for rare diseases, while pediatric exclusivity encourages sponsors to conduct clinical studies in pediatric populations. Similarly, the GAIN Act was introduced to stimulate the development of antibacterial and antifungal drugs needed to combat antimicrobial resistance. The 3 years exclusivity provision, in contrast, primarily rewards sponsors for conducting additional clinical investigations that support new uses, new dosing regimens, or other clinically meaningful changes to already approved drug products.
An application may qualify for 3-year exclusivity if it is a New Drug Application (NDA) submitted under section 505(b)(1) or 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or a supplement to an existing NDA. The eligibility criteria are clearly defined in the statute and further elaborated in the draft guidance. First, the exclusivity may apply to a drug product that contains an active moiety previously approved in another 505(b) application. In other words, the active ingredient itself is not entirely new. This provision therefore applies to products that represent modifications or improvements to already approved drugs. In the case of fixed-combination drug products, the exclusivity may apply when each of the active moieties has already been approved in another 505(b) application. Second, the application must contain reports of “new clinical investigations,” other than simple bioavailability studies. These investigations must be essential to the approval of the NDA or supplement and must have been conducted or sponsored by the applicant seeking the exclusivity. The requirement that the investigations be essential ensures that exclusivity is granted only when the clinical data meaningfully contribute to the regulatory decision-making process.
The US FDA clarifies that an investigation is not considered essential simply because the applicant conducted the study and submitted the results as part of the application. Rather, the determination of whether a study is essential depends on whether no other available data could support the approval of the application. If the same approval decision could have been made based on previously available evidence, the study may not qualify as essential.
From a regulatory submission perspective, the request for 3-year exclusivity must be included in the Module 1 folder of the NDA submission. Module 1 of the Common Technical Document contains region-specific administrative information, and the FDA expects sponsors to clearly identify exclusivity requests within this section. Once granted, the exclusivity information is reflected in the FDA’s approved drug products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. In the Orange Book, 3-year exclusivity is represented by a letter code (and occasionally a numeric code) that may also be accompanied by a brief description of the protected change or clinical investigation. The US FDA does not send a separate notification to the application holder specifying the duration of exclusivity. Instead, the Orange Book serves as the official and publicly accessible source of information regarding exclusivity periods for approved drug products.
To demonstrate that the NDA contains qualifying new clinical investigations, the applicant must submit a certification statement. In this certification, the sponsor must confirm, to the best of its knowledge, several key points. First, each of the clinical investigations must involve human subjects. Preclinical studies or animal experiments alone are not sufficient to support eligibility for this exclusivity. Second, the results of the investigations must not have been previously relied upon by the US FDA to demonstrate substantial evidence of effectiveness for an already approved drug product for any indication, or to establish safety for a new patient population. Third, the investigations must not duplicate the results of another study that the Agency previously relied upon to demonstrate effectiveness or safety for a new patient population of a previously approved drug product.
The draft guidance also provides important clarification regarding cohorts or treatment arms within clinical studies. In some cases, a particular cohort or treatment arm within a broader clinical trial may qualify as a distinct new clinical investigation. This may occur even if the US FDA has previously relied upon results from a different cohort or treatment arm within the same overall study for approval of another application or supplement. To determine whether such a cohort or treatment arm qualifies as a new clinical investigation, the US FDA employs a multifactorial and case-by-case approach. Several considerations may influence the Agency’s decision. For example, the US FDA may examine whether there is a scientifically or medically valid rationale for studying the separate cohort or treatment arm. The Agency may also assess whether the cohort evaluates different patient populations, disease conditions, or drug products. Additionally, the US FDA may consider whether the cohort or treatment arm was pre-specified in the clinical study protocol, which would demonstrate that the investigation was planned prospectively rather than added retrospectively.
The statutory foundation for these regulatory pathways can be traced to the Drug Price Competition and Patent Term Restoration Act of 1984, widely known as the Hatch-Waxman Amendments. This landmark legislation introduced a regulatory framework that attempted to balance two important objectives. On the one hand, the government sought to encourage pharmaceutical innovation by granting incentives such as patent term extensions and regulatory exclusivities. On the other hand, it also aimed to facilitate the availability of lower-cost generic medicines by establishing the Abbreviated New Drug Application pathway.
The Hatch-Waxman Amendments added section 505(b)(2) and section 505(j) to the Federal Food, Drug, and Cosmetic Act. Section 505(b)(2) created a pathway for drug products that rely partly on previously published literature or the US FDA’s findings for an already approved drug. This pathway has enabled the development of differentiated products, such as new formulations, new dosage forms, or new routes of administration. Section 505(j), meanwhile, established the ANDA pathway for generic drugs that demonstrate bioequivalence to a reference listed drug without repeating extensive clinical trials.
It is also important to recognize that regulatory exclusivity is distinct from patent protection, even though the two mechanisms often operate together. Patent rights (relying on novelty, non-obviousness and commercial viability) are granted by the patent office i.e., United States Patent and Trademark Office, in this case and may cover a wide variety of innovations, including chemical compounds, manufacturing processes, formulations, medical devices, and other technologies. Patents provide the holder with the legal right to exclude others from making, using, or selling the patented invention for a specified period. Regulatory exclusivity, by contrast, is granted by the drug regulatory authority, in this case the US FDA. It prevents competitors from marketing a product. The policy objective is to reward companies that invest resources in generating new clinical evidence that advances drug development. The duration of a patent generally extends for 20 years from the date on which the patent application was filed in the United States, although patent term adjustments and extensions may alter the effective protection period. Regulatory exclusivities, on the other hand, have fixed durations defined by statute, such as five years for new chemical entities or three years for qualifying new clinical investigations.
Importantly, the periods of patent protection and regulatory exclusivity may or may not run concurrently. Some drug products benefit from both forms of protection, while others may have only one or neither. In some cases, exclusivity may expire before the relevant patents, whereas in other situations exclusivity may provide protection even after certain patents have lapsed. Moreover, patents and exclusivities may cover different aspects of a drug product, such as the active ingredient, formulation, manufacturing process, or approved therapeutic use.
The US FDA maintains updated records of both patents and exclusivities in the Orange Book. Once patents or exclusivities expire, they are removed from the Orange Book, thereby signalling competing products may proceed through the regulatory approval process without the same legal barriers.
(The author is a New Delhi based academician and R&D consultant)
|